Ufp Technologies Inc (UFPT)

UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer ConferenceJuly 1, 2026 3:08 PM
Business Wire UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, President and Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer and Chief Financial Officer, will present and host 1x1 meetings at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026 in White Plains, NY. About UFP Technologies, Inc. UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics and spine and wound care. For more information, visit ufpt.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260701297831/en/ Ron Lataille, CFO, UFP Technologies, Inc., tel. 978-234-0926
rlataille@ufpt.com Original: UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference

UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th in New York, NYJune 4, 2026 3:31 PM
Business Wire UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer and Chief Financial Officer, will present at the East Coast IDEAS Investor Conference on Wednesday, June 10, 2026 at The Westin Times Square in New York, NY. UFP’s presentation is scheduled to begin at 7:55 AM ET. The presentation is webcast and can be accessed through the conference host’s main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the company's website: https://ufpt.com/Investors/. About IDEAS Investor Conferences The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “SPONSORED BY INVESTORS. FOR INVESTORS.” and for the benefit of regional investment communities. Conference sponsors collectively have more than $200 billion in assets under management and include: 1102 Partners, Adirondack Research and Management, Allianz Global Investors: NFJ Investment Group, Ariel Investments, Aristotle Capital Boston, Ascend Wealth Advisors, Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management, Constitution Research & Management, Inc., Diamond Hill, First Wilshire Securities Management, Inc., Granahan Investment Management, Great Lakes Advisors, Greenbrier Partners Capital Management, LLC, Hodges Capital Management, Ironwood Investment Management, Keeley Teton Advisors, Luther King Capital Management, Marble Harbor Investment Counsel, North Star Investment Management, Punch & Associates, Shepherd Kaplan Krochuk, Westwood Holdings Group, Inc., and William Harris Investors. The IDEAS Investor Conferences are held annually and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com. If interested in participating or learning more about the IDEAS conferences, please contact Lacey Wesley at (817) 769 -2373 or lWesley@IDEASconferences.com. About UFP Technologies, Inc. UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics and spine and wound care. For more information, visit ufpt.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260604994773/en/ Ron Lataille, CFO, UFP Technologies, Inc., tel. 978-234-0926
rlataille @mikey-9014
jelliott@threepa.com Original: UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th in New York, NY

UFP Technologies Names Ryan Stafford General Counsel and Senior Vice President of Human ResourcesJune 4, 2026 3:29 PM
Business Wire Seasoned Legal Executive Brings Nearly Two Decades of Public Company and M&A Leadership to Newburyport-Based Medical Device CDMO UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization specializing in single-use and single-patient medical devices, today announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeds Chris Litterio, who is retiring after having played a pivotal role in the company’s growth. Stafford brings nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. All of these capabilities are directly aligned with UFP Technologies’ continued growth strategy. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. (Nasdaq: LFUS), a global manufacturer of electrical protection components. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. “We are thrilled to welcome Ryan Stafford to UFP Technologies,” said Mitch Rock, Chief Executive Officer of UFP Technologies. “Ryan brings exceptional depth of experience supporting growth-oriented public companies and a proven ability to lead acquisitions. His strategic perspective, legal expertise, and track record of building high-performing teams will be invaluable as we continue to scale the business. “I am excited to join UFP Technologies at such a dynamic moment in its evolution,” said Stafford. “The company has built an outstanding reputation as a trusted partner to leading medical device manufacturers, and I look forward to supporting its continued through strategic acquisitions and by strengthening the organization to scale with that growth.” Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law. About UFP Technologies, Inc. UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds, infection control, cardiovascular, orthopedics and spine and wound care. For more information, visit ufpt.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260604211242/en/ Ron Lataille
978-234-0926, rlataille@ufpt.com Original: UFP Technologies Names Ryan Stafford General Counsel and Senior Vice President of Human Resources

UFP Technologies Announces Strong Q1 ResultsMay 4, 2026 4:43 PM
Business Wire UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.5 million for its first quarter ended March 31, 2026, 1.8% higher than net income of $17.2 million for the first quarter of 2025. Net sales for the quarter ended March 31, 2026 were $154.2 million, 4.1% higher than 2025 first quarter sales of $148.1 million. GAAP and adjusted earnings per diluted common share outstanding (“EPS”) for the quarter ended March 31, 2026 were $2.24 and $2.48, respectively. Throughout this news release, reference is made to non-GAAP measures including organic sales growth, adjusted gross margin, adjusted operating income, adjusted SG&A, adjusted net income and EPS, and EBITDA and adjusted EBITDA. Please see “Non-GAAP Financial Information” at the end of this news release. “I am pleased with our first quarter results and continued progress with our strategic initiatives,” said R. Jeffrey Bailly, Chairman and CEO. “Revenue grew 4.1%, driven by a 5.9% increase in our medical sales. This was offset by a 15% decline in our non-medical sales as we continue to focus our efforts on high-growth opportunities in the MedTech space. Our robotic surgery, patient surfaces and support, and interventional and surgical segments showed the strongest growth at 7%, 11%, and 15%, respectively. To increase capacity to meet strong forecasted demand, in Q2 we will take possession of two new facilities in the Dominican Republic – one in La Romana to support continued growth in our robotic surgery business, and one in Santiago to support growth and additional program transfers in the safe patient handling space.” “EPS growth of 1.4% was slower than revenue growth, due in part to softer results at our AJR operation related to continued E-Verify labor inefficiency costs,” Bailly said. “We also absorbed the start-up expenses associated with four large programs that are currently ramping and expected to be significant contributors in the second half of the year.” “Our recent acquisitions are all performing well and the integrations are essentially complete. And we continue to evaluate new acquisition opportunities that will further increase our value to customers,” said Bailly. “With our strong balance sheet, healthy pipeline of new growth opportunities, ramping newly launched programs, and a strong backlog, we remain very bullish about our future.” Financial Highlights: Sales for the first quarter increased 4.1% to $154.2 million, from $148.1 million in the same period of 2025. Organic sales were essentially flat for the quarter ended March 31, 2026 as compared to the same period in 2025. First quarter sales to the medical market increased 5.9% to $143.4 million. Non-medical sales for the first quarter decreased 15.0% to $10.8 million. Gross profit as a percentage of sales (“gross margin”) increased to 28.8% for the first quarter of 2026, from 28.5% in the same quarter of 2025. Selling, general and administrative expenses (“SG&A”) increased 12.3% to $21.0 million for the first quarter of 2026 compared to $18.7 million in the same quarter of 2025. As a percentage of sales, SG&A increased to 13.6% in the first quarter of 2026, from 12.6% in the same period of 2025. As a percentage of sales, adjusted SG&A increased in the first quarter of 2026 to 12.0% from 11.0% in the same period of 2025. For the first quarter of 2026, operating income increased 1.0% to $23.4 million, from $23.1 million in the same quarter of 2025. Adjusted operating income for the first quarter of 2026 remained consistent at $25.8 million compared to the first quarter of 2025. Net income was $17.5 million in the first quarter of 2026, compared to $17.2 million in the same period of 2025. Adjusted net income increased 0.6% to $19.3 million in the first quarter of 2026, from $19.2 million in the same period of 2025. GAAP and adjusted EPS for the first quarter of 2026 were $2.24 and $2.48, respectively, as compared to $2.21 and $2.47, respectively, for the same period in 2025. Adjusted EBITDA for the first quarter of 2026 increased to $31.0 million from $30.2 million in the first quarter of 2025. About UFP Technologies, Inc. UFP Technologies is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. UFP is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.   Consolidated Condensed Statements of Income (in thousands, except per share data) (Unaudited)     Three Months Ended   March 31,     2026     2025 Net sales $ 154,202     $ 148,148 Cost of sales 109,840     105,997 Gross profit 44,362     42,151 Selling, general & administrative expenses 21,021     18,725 Acquisition costs —     37 Change in fair value of contingent consideration —     263 Gain on disposal of property, plant & equipment (26 )   — Operating income 23,367     23,126 Interest expense, net 1,737     2,809 Other expense 22     36 Income before income tax expense 21,608     20,281 Income tax expense 4,113     3,097 Net income $ 17,495     $ 17,184         Net income per share $ 2.27     $ 2.24 Net income per diluted share $ 2.24     $ 2.21         Weighted average common shares outstanding 7,721     7,688 Weighted average diluted common shares outstanding 7,799     7,776   Consolidated Condensed Balance Sheets (in thousands) (Unaudited)     March 31, 2026   December 31, 2025 Assets:       Cash and cash equivalents $ 19,976   $ 20,301 Receivables, net   98,566     82,914 Inventories   93,983     86,856 Other current assets   11,581     10,930 Net property, plant, and equipment   78,396     79,109 Goodwill   196,648     197,403 Intangible assets, net   137,856     140,849 Other assets   37,678     36,715 Total assets $ 674,684   $ 655,077 Liabilities and equity:       Accounts payable $ 27,026   $ 24,289 Current installments, net of long-term debt   12,500     12,500 Other current liabilities   37,487     38,073 Long-term debt, excluding current installments   125,110     122,955 Other liabilities   33,686     33,383 Total liabilities   235,809     231,200 Total equity   438,875     423,877 Total liabilities and stockholders' equity $ 674,684   $ 655,077 Conference Call The Company has scheduled a conference call on Tuesday, May 5, 2026, at 8:30 AM Eastern time. Participants may join the call using the following dial-in numbers: Toll-Free: 1-412-206-6478 International: 1-833-890-4010 A live webcast of the conference call and accompanying materials will be available at www.ufpt.com. A replay of the webcast will be accessible following the event on the Company’s Investor Relations website at https://ufpt.com/investors/. Forward-Looking Statements Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to known and unknown risks, uncertainties, and other factors, which may cause our or our industry’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. Such statements include, but are not limited to, statements about the Company’s future financial or operating performance; statements of the Company about the marketplace and the Company’s position in the marketplace; statements about the Company’s acquisition strategies and opportunities and the Company’s growth potential and strategies for growth; statements about the integration and performance of recent acquisitions, including that such acquisitions will be accretive to the Company's revenue, income and EBITDA; statements about the Company’s ability to realize the benefits expected from our pipeline of acquisition opportunities and recently completed acquisitions, including any related synergies; expectations regarding an increase in revenue as a result of the Company’s new robotic programs and facilities expansions in the Dominican Republic and the completion of program transfers to the Dominican Republic in the safe patient handling space; statements about the Company’s ability to realize the benefits expected from our four large programs; expectations regarding an increase in product demand as a result of negotiating favorable terms with the Company’s largest customer; expectations regarding customer demand; , and any indication that the Company may be able to sustain or increase its sales, earnings or earnings per share, or its sales, earnings or earnings per share growth rates. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the Company's general ability to execute its business plans; industry conditions, including fluctuations in supply, demand and prices for the Company's products and services due to inflation or otherwise; risks associated with governmental regulations and/or sanctions affecting the import and export of products, including global trade barriers, additional taxes, tariff increases or uncertainties, cash repatriation restrictions, retaliations and boycotts between the U.S. and other countries; risks associated with domestic, regional and global political risks and uncertainties, including the ongoing conflict between the U.S. and Iran; risks relating to cyber security, such as cyber-attacks on the Company’s information technology infrastructure, products, suppliers, customers and partners, including the potential consequences of the Cyber Incident (as defined in Item 1C, Cybersecurity in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025) could result in data or financial loss, reputational harm, business disruption, damage to our relationships with customers, consumers, employees and third parties on which we rely, litigation, regulatory investigations, enforcement actions or other negative impacts under cybersecurity related regulations or otherwise; risks associated with our or third-party use of artificial intelligence technologies; risks related to our indebtedness and compliance with covenants contained in our financing arrangements, and whether any available financing may be sufficient to address our needs; risks relating to delayed payments by our customers and the potential for reduced or canceled orders; risks related to customer concentration; risks associated with new product and program launches; risks relating to our performance and the performance of our counterparties under the agreements we have entered into; the risk that our two largest customers, on whom we depend for a substantial portion of our annual revenues, will not purchase the expected volume of goods under the supply agreements we have entered into with them because, among other things, they no longer require the products at all or to the degree they anticipated or because, among other things, our largest customers decide to manufacture the products itself or through one of its affiliates it obtains the products from other listed suppliers specified in our agreement; risks associated with our inability to extend or otherwise renegotiate favorable terms with the Company's largest customer, if at all; the risk that we will not achieve expected rebates under the applicable supply agreement; risks relating to our ability to maintain increased levels of production at profitable levels, if at all; or to continue to increase production rates and/or timely and successfully transfer programs to the Dominican Republic and risks relating to disruptions and delays in our supply chain or labor force; risks relating to our new robotic programs and facilities expansions in the Dominican Republic risks associated with the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions, the integration of any such acquisition candidates, the value of those acquisitions to our customers and shareholders, and the financing of such acquisitions; and other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's filings with the Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which any such statement is based. Forward-looking statements are also subject to the risks and other issues described above under “Use of non-GAAP Financial Information,” which could cause actual results to differ materially from current expectations included in the Company’s forward-looking statements included in this press release. Non-GAAP Financial Information This news release includes non-generally accepted accounting principles (“GAAP”) performance measures. Management considers organic sales growth, adjusted gross margin, adjusted SG&A, adjusted operating income, adjusted net income and EPS, EBITDA, and adjusted EBITDA, non-GAAP measures. The Company uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company’s historical operating results. The Company’s management believes these non-GAAP measures are useful in evaluating the Company’s operating performance and are similar to measures reported by publicly listed U.S. competitors, and regularly used by securities analysts, institutional investors, and other interested parties in analyzing operating performance and prospects. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. By providing these non-GAAP measures, the Company’s management intends to provide investors with a meaningful, consistent comparison of the Company’s performance for the periods presented. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures of performance used by other companies in other industries or within the same industry.   Organic Sales Growth Rate Reconciliation (in thousands)     Three Months Ended   March 31,     2026     2025 Overall net sales $ 154,202     $ 148,148 Net sales from acquired operations   (5,506 )     — Organic sales $ 148,696     $ 148,148         Organic growth sales rate   0.4 %       Adjusted Gross Margin (in thousands)     Three Months Ended   March 31,     2026       2025   Overall net sales (GAAP) $ 154,202     $ 148,148   Gross profit (GAAP)   44,362       42,151   Gross margin (GAAP)   28.8 %     28.5 % Adjustments:   Purchase accounting expenses — —   Adjusted gross profit 44,362     42,151   Adjusted gross margin   28.8 %     28.5 %   Adjusted Selling, General and Administrative Expenses (SG&A) (in thousands)     Three Months Ended   March 31,     2026       2025   SG&A (GAAP) $ 21,021     $ 18,725   Amortization of intangible assets   (2,481 )     (2,387 ) Adjusted SG&A $ 18,540     $ 16,338   Adjusted SG&A as a % of sales   12.0 %     11.0 %   Adjusted Operating Income Reconciliation (in thousands)     Three Months Ended   March 31,     2026     2025 Operating income (GAAP) $ 23,367     $ 23,126 Adjustments:       Acquisition costs   —       37 Change in fair value of contingent consideration   —       263 Amortization of intangible assets   2,481       2,387 Gain on disposal of fixed assets   (26 )     — Adjusted operating income (Non-GAAP) $ 25,822     $ 25,813   Adjusted Net Income per Diluted Common Share Outstanding Reconciliation (in thousands, except per share data)     Three Months Ended   March 31,     2026       2025   Net income (GAAP) $ 17,495     $ 17,184   Adjustments (net of taxes):       Acquisition costs   —       37   Change in fair value of contingent consideration   —       263   Amortization of intangible assets   2,481       2,387   Gain on disposal of fixed assets   (26 )     —   Taxes on adjustments   (632 )     (665 ) Adjusted net income (Non-GAAP) $ 19,318     $ 19,206           Adjusted net income per diluted share outstanding (Non-GAAP) $ 2.48     $ 2.47   Weighted average diluted common shares outstanding   7,799       7,776     EBITDA Reconciliation (in thousands)     Three Months Ended   March 31,     2026     2025 Net income (GAAP) $ 17,495     $ 17,184 Income tax expense   4,113       3,097 Interest expense, net   1,737       2,809 Depreciation   2,418       2,247 Amortization of intangible assets   2,481       2,387 EBITDA (Non-GAAP) $ 28,244     $ 27,724 Adjustments:       Share based compensation   2,733       2,212 Acquisition costs   —       37 Change in fair value of contingent consideration   —       263 Gain on disposal of fixed assets   (26 )     — Adjusted EBITDA (Non-GAAP) $ 30,951     $ 30,236   View source version on businesswire.com: https://www.businesswire.com/news/home/20260504755846/en/ Ron Lataille
978-234-0926 Original: UFP Technologies Announces Strong Q1 Results

News; $UFPT UFP Technologies Announces Q3 Results

NEWBURYPORT, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), an innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market, today reported net income of $3.0 million or $0.40 per dilu...

In case you are interested UFPT - UFP Technologies Announces Q3 Results

Surprised this board is empty. I am/will be a long-term holder of this company until the indefinite future, pending no major shift in fundamentals/management style.

Anyone still following this since 2008? I recently picked up a few.

$14.10! Very NICE! woohoo!

Not looking to bad guys!!

Anyone want to be an Assistant on here? PM ME!

I am expecting to sell at $15

What a good Green day today!

Thanks for telling me to pull my head out, and look at the chart - lol.......I joined you at the open today, and what can I say - WOW.......

Thanks again !!

Budget

UFPT! Weeee!!! I love this!

You know, I believe you are absolutely correct.....I was basing my assumption on some erroneous data I had......lol.

Thanks.....

Budget

I dont really think you missed it. check out the chart.

Hey, GoldenZ - nice new board......I completely missed this play, but will watch you guys get rich......lol.

Good luck !!

Budget

Bought UFPT today @ 10.36, 1k shares

New Board! Welcome ALL!